---
title: "CRNX: Pipeline advances in acromegaly, CAH, and NETs, with strong financial runway into 2030"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293389069.md"
description: "A robust pipeline targets major endocrine diseases, with PALSONIFY showing strong launch metrics and clinical efficacy in acromegaly. Atumelnant and CRN09682 advance in late-stage trials for CAH, Cushing's, and neuroendocrine tumors. $1.3B cash funds operations into 2030.Original document: Crinetics Pharmaceuticals, Inc. [CRNX] Slides Release — Jul. 21 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-07-21T21:25:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293389069.md)
  - [en](https://longbridge.com/en/news/293389069.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293389069.md)
---

# CRNX: Pipeline advances in acromegaly, CAH, and NETs, with strong financial runway into 2030

A robust pipeline targets major endocrine diseases, with PALSONIFY showing strong launch metrics and clinical efficacy in acromegaly. Atumelnant and CRN09682 advance in late-stage trials for CAH, Cushing's, and neuroendocrine tumors. $1.3B cash funds operations into 2030.

Original document: Crinetics Pharmaceuticals, Inc. \[CRNX\] Slides Release — Jul. 21 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [CRNX.US](https://longbridge.com/en/quote/CRNX.US.md)

## Related News & Research

- [Bank of America Corp DE Sells 85,189 Shares of Crinetics Pharmaceuticals, Inc. $CRNX](https://longbridge.com/en/news/296069006.md)
- [Crinetics-Vertex deal clears US antitrust waiting period, other approvals in hand](https://longbridge.com/en/news/295935333.md)
- [Elicera corrects CARMA update, says 2 of 3 prior CAR T patients show tumor response, not all 3](https://longbridge.com/en/news/295928409.md)
- [AEMD: Final oncology trial cohort underway, strong cash position, and expanded research into new indications](https://longbridge.com/en/news/295851387.md)
- [Guardant Health Sees Shield, MRD and Oncology Testing Growth Accelerate](https://longbridge.com/en/news/295883943.md)